Disease: Respiratory syncytial virus infection

Geismar

United Kingdom
|
2020-2022
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Community
  • Household
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Okay

Türkiye
|
2021-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Respiratory syncytial virus

Rupp

Switzerland
|
2009-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus

FIDO

United Kingdom Ireland
|
2022-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination

Ehlmaier

Austria
|
2021-2022
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Primary care
  • Respiratory syncytial virus

Raguž

Bosnia and Herzegovina
|
2008-2022
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

Ferrari

Italy
|
2022-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus

Havlin

Czech Republic
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination
  • Arexvy

Korkmaz

Türkiye
|
2022-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus

Savino

Italy
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus

Barbas Del Buey

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Community
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab